http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-885081-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c902faf6ae746c51fc8010672fc22894 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-621 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-42 |
| filingDate | 1959-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1961-12-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-885081-A |
| titleOfInvention | Improvements in or relating to therapeutic compositions containing (acetylsalicylic acid)-anhydride |
| abstract | Stable, solid preparations for oral administration comprise [acetylsalicylic acid]-anhydride and a pharmaceutically acceptable, non-alkaline diluent containing at least 3% by weight of the said anhydride of an acid substance, which diluent does not lower substantially the melting-point of the said anhydride. Specified acidic substances are sodium biphosphate, citric acid, pyridexine hydrochloride, tartaric acid, malic acid (all preferred), ascorbic acid, alkali metal bitartrates and biphosphates, glutamic acid hydrochloride, picotinic acid, acidic amino acids, salts of amino acids, succinic acid, glucuronic acid, glutaric acid, pimelic acid, malonic acid, mandelic acid, adipic acid, tricarballylic acid and mixtures thereof. The preparations may include pharmaceutically acceptable non-alkaline carriers, diluents, excipients, binders, lubricants, adhesives, disintegrators. They may be put up in solid oral dosage unit forms, e.g. tablets, capsules, pills, powder packets, effervescent granules, pilules, wafer, chewing gum, cachets, pellets and sustained release, delayed action or enteric pharmaceutical forms. Such unit dosage forms are preferably anhydrous for reasons of stability and may contain additional active ingredients, e.g. other analgesics, those specified being acetophenetidin, salicylamide, and N-acetyl-paraaminophenol, caffeine (stimulant), codeine (antitussive), cortisone, hydrocortisone, 6-methyl - D 1 - hydrocortisone, prednisone, prednisolone, their esters and salts of their acid esters (anti-inflammatory steroids), antibiotics, e.g. penicillin V, antibistaminics, reserpine and chlorpheniramine maleate. |
| priorityDate | 1958-04-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 77.